Improved beta-cell function after treatment with testosterone undecanoate
- The insulinotropic effect of testosterone reported in the present study is especially interesting when considering that there is a progressive deterioration in beta-cell function in type 2 diabetes, and that early treatment can reverse beta-cell function impairment.
What is known about obesity-related secondary hypogonadism
What this study adds
Figure 1. Changes in body composition after testosterone undecanoate treatment for at least 6 months.
Figure 2. Changes in beta-cell function after testosterone undecanoate treatment for at least 6 months.
Nevertheless, the insulinotropic effect of testosterone reported in the present study is especially interesting when considering that there is a progressive deterioration in beta-cell function in type 2 diabetes.25 Pancreatic islet function is about 50% of normal at the time of type 2 diabetes diagnosis.25 Impaired beta-cell function (and possibly beta-cell mass) appears to be reversible, particularly at early stages of the disease where the limiting threshold for reversibility has probably not been passed.25 Improved beta-cell function is likely a mechanism contributing to remission of type 2 diabetes that has been reported with long-term testosterone undecanoate treatment.26 This highlights the importance of starting testosterone treatment as early as possible in hypogonadal men, when the “window of reversibility” of impaired beta-cell function is still open.
- Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol. 2010;316(2):180-186. Return to content
- Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52(1):49−51. Return to content
- Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2013;78(3):330-337. Return to content
- Barazzoni R, Gortan Cappellari G, Ragni M, Nisoli E. Insulin resistance in obesity: an overview of fundamental alterations. Eating and weight disorders : EWD. 2018. Return to content
- Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-2641. Return to content
- Dimitriadis GK, Randeva HS, Aftab S, et al. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018. Return to content
- Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92(2):549-555. Return to content
- Escobar-Morreale HF, Santacruz E, Luque-Ramirez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017;23(4):390-408. Return to content
- Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature reviews Endocrinology. 2013;9(8):479-493. Return to content
- Dhindsa S, Ghanim H, Batra M, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016;39(1):82-91. Return to content
- Sattler F, He J, Chukwuneke J, et al. Testosterone Supplementation Improves Carbohydrate and Lipid Metabolism in Some Older Men with Abdominal Obesity. Journal of gerontology & geriatric research. 2014;3(3):1000159. Return to content
- Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. Return to content
- Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837. Return to content
- Kelly DM, Akhtar S, Sellers DJ, Muraleedharan V, Channer KS, Jones TH. Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse. Endocrine. 2016;54(2):504-515. Return to content
- Praveen EP, Khurana ML, Kulshreshtha B, et al. Plasma testosterone in adult normoglycaemic men: impact of hyperinsulinaemia. Andrologia. 2012;44(5):293-298. Return to content
- Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic beta-cell function: review of methods and clinical applications. Current diabetes reviews. 2014;10(1):2-42. Return to content
- Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care. 2004;27(6):1487-1495. Return to content
- Grillo ML, Jacobus AP, Scalco R, et al. Testosterone rapidly stimulates insulin release from isolated pancreatic islets through a non-genomic dependent mechanism. Horm Metab Res. 2005;37(11):662-665. Return to content
- Navarro G, Xu W, Jacobson DA, et al. Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. Cell metabolism. 2016;23(5):837-851. Return to content
- Mauvais-Jarvis F. Role of Sex Steroids in beta Cell Function, Growth, and Survival. Trends in endocrinology and metabolism: TEM. 2016;27(12):844-855. Return to content
- Xu W, Niu T, Xu B, Navarro G, Schipma MJ, Mauvais-Jarvis F. Androgen receptor-deficient islet beta-cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse. J Diabetes Complications. 2017;31(5):787-795. Return to content
- Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond). 2016;40(1):162-170. Return to content
- Yassin AA, Nettleship J, Almehmadi Y, Salman M, Saad F. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016:Jan 14. doi: 10.1111/and.12514. [Epub ahead of print]. Return to content
- Saad F. Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism). Adv Exp Med Biol. 2017;1043:527-558. Return to content
- Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218. Return to content
- Haider A, Haider KS, Saad F. Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. Endocrinology, diabetes & metabolism case reports. 2017;2017. Return to content